21st Oct 2013 08:02
LONDON (Alliance News) - Specialty pharmaceutical company Oxford Pharmascience Group PLC Monday said it has completed formulation of a "Gastric Safe" 400 milogram Ibuprofen tablet as it proceeds towards clinical pilot testing.
The company, which redevelops medicines to make them safer and easier to take, said it is now on track to start clinical pilot testing in early 2014.
Oxford Pharmascience shares were up 5.9% at 4.525 pence Monday morning.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group